Help your adult patients with Crohn's disease
Get an individualized prognostic risk profile with CDPATH.
CDPATH is an innovative, validated prognostic tool that uses blood tests* to evaluate an adult Crohn’s disease (CD) patient's potential risk for developing serious complications† within 3 years.1
Healthcare professionals (HCPs) should not rely primarily on the risk predictions from CDPATH to make a clinical diagnosis or treatment decision regarding an individual patient.About CDPATH
*The CDPATH risk assessment tool was developed and validated by Prometheus Laboratories Inc., a partner of Takeda. Test results are provided via Prometheus Laboratories Inc. to physicians.
†Serious complications are defined as bowel strictures, internal penetrating disease, or non-perianal surgery (bowel resection or stricturoplasty).